Drug-drug interactions in the treatment of HCV among people who inject drugs

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Mauss, Stefan ^a   Klinker, Hartwig ^b  

^a Center for HIV and Hepatogastroenterology   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Addiction; Boceprevir; Drug interactions; Drugs; HCV; Mental health; Telaprevir

Indexed keywords

ALPRAZOLAM; BOCEPREVIR; BUPRENORPHINE; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DARUNAVIR; DIAMORPHINE; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; LOPINAVIR; METHADONE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PREGABALIN; RITONAVIR; SERTRALINE; TELAPREVIR; TETRAHYDROCANNABINOL; UNINDEXED DRUG; ZOLPIDEM;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; GENOTYPE; HEART ARRHYTHMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAVENOUS DRUG ABUSE; OPIATE SUBSTITUTION TREATMENT; PLASMA CONCENTRATION-TIME CURVE; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN BINDING;

ADDICTION; BOCEPREVIR; DRUG INTERACTIONS; DRUGS; HCV; MENTAL HEALTH; TELAPREVIR;

ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84881009189     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit299     Document Type: Article

References (25)

1. Bräu N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ fullcourse vs. 16-week delayed ribavirin. Hepatology 2004; 39: 989-98.
2. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-5.
3. Ghosal A, Yuan Y, Tong W, Su AD, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39: 510-521.
4. van Heeswijk RP, Boogaerts G, Paepe de E, Solingen-Ristea van R, Garg VBeumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir. In: Fifth international workshop on clinical pharmacology of hepatitis therapy. 23-24 June, 2010:12.
5. Hulskotte EGJ, Gupka S, Xuan Y, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. In: Sixteenth annual meeting of HEP DART. Koloa, Hawaii. 4-8 December, 2011:121.
6. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, van Heeswijk RP. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012; 52: 1566-73.
7. Luo X, van Heeswijk RP, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers. In: Sixth international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MA. 22-23 June, 2011:PK-11.
8. van Heeswijk RP, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V. Pharmacokinetic Interaction between Telaprevir and Methadone. Antimicrob Agents Chemother. 2013; 57: 2304-9.
9. Hulskotte EGJ, Feng HP, Bruce RD, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. In: Seventh international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MS, USA. 27-28 June, 2012:PK-09.
10. Poordad F, Lawitz E, Gordon SC, et al. Concomitant medication use in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. In: The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA. 9-13 November, 2011:937.
11. Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/ naloxone maintenance therapy. Antimicrob Agents Chemother. 2012; 56: 3641-7.
12. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabiol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 2006; 28: 447-53.
13. van Heeswijk RP, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers. In: 18th Conference on retroviruses and Opportunistic infections. Boston, MA. 27 February - 2 March, 2011:119.
14. Sulkowski M, Sherman KE, Soriano V, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. In: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA. 9-13 November, 2012:54.
15. Kakuda T, Leopold L, Nijs S, et al. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: a randomised, two-way crossover trial. In: 13th InternationalWorkshop on Clinical Pharmacology of HIV Therapy. 16-18 April, 2012, Barcelona:O-18.
16. Wenning L, Flexner C, Liu R, et al. Assessment of boceprevir pharmacokinetic/ pharmacodynamic relationships for sustained viral response and occurrence of anemia: Results in HCV/HIV co-infected patients. In: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA. 9-13 November, 2012:770.
17. Lee JE, van Heeswijk RP, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-74.
18. Garg V, van Heeswijk RP, Eun Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of ciclosporine and tacrolimus. Hepatology 2011; 54: 20-7.
19. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and ciclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-30.
20. Hulskotte E, Feng HP, Xuan F, et al. Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin. Antimicrob Agents Chemother 2013; 57: 2582-8.
21. Jumes P, Feng HP, Xuan Y, Youngberg S, Wagner J, Butterton J. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers. In: Seventh international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MS, USA. 27-28 June, 2012:PK-05.
22. Garg V, Yang Y, Smith F, Adda N, van Heeswijk RP. The pharmacokinetic interaction on oral contraceptive containing ethinyl estradiol and northindrone and telaprevir. In: Sixth international workshop on clinical pharmacology of hepatitis therapy. Cambridge, MA. 22-23 June, 2011:PK-17.
23. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.
24. Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions [Epub ahead of print 5 November 2012]. J Hepatol 2012; pii: S0168-8278(12)00828-8. doi:10.1016/j.jhep. 2012.10.027.
25. Ouwerkerk-Mahadevan S, Simion A, Spittaels K, Peeters m, Beumont- Mauviel M. No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive ethinylestradiol and norethindrone. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA, USA. 9-13 November, 2012, Hepatology 2013; 56 (Suppl): 565A.